How is the company managing the impact of biosimilar competition on Stelara sales?

Stelara sales experienced a significant 33.7% decline due to biosimilar competition. Johnson & Johnson anticipates continued launches of biosimilar versions of Stelara in 2025, which will impact future sales of the product. The company is focusing on growth drivers in other areas of its portfolio to offset these declines.

What is the impact of recent acquisitions on the company's financial performance?

The company completed the acquisition of Shockwave Medical in the MedTech segment, which contributed to the segment's 2.5% sales growth. Additionally, subsequent to the quarter, J&J acquired Intra-Cellular Therapies, Inc. for approximately $14.6 billion, funded by cash and debt issuance, which is expected to contribute to the Innovative Medicine segment.

What is the company's outlook regarding its ongoing legal proceedings, particularly concerning talc and opioids?

The company continues to address its legal liabilities. While the talc bankruptcy case was dismissed, leading to a reversal of a significant portion of the reserve, the company still has approximately $4.2 billion reserved for talc matters. For opioid litigation, approximately 70% of the $5.0 billion settlement has been paid, with an estimated $1.5 billion remaining to settle these claims. The company believes it has sufficient liquidity to manage these obligations.

JNJ 10-Q Quarterly Report Q1 FY2025 — Revenue, Net Income, EPS

Q: What was the primary driver for the significant increase in net earnings this quarter?

The primary driver for the substantial increase in net earnings to $11.0 billion was the reversal of approximately $7.0 billion related to the previously accrued talc reserve. This one-time item significantly boosted the 'Other (income) expense, net' category.

Summary

Johnson & Johnson (JNJ) reported a strong first quarter for fiscal year 2025, with worldwide sales reaching $21.9 billion, a 2.4% increase year-over-year. This growth was driven by a robust operational increase of 4.2%, partially offset by a 1.8% negative currency impact. The Innovative Medicine segment showed resilience with a 2.3% sales increase, fueled by strong performance in Oncology, particularly with products like Darzalex and CARVYKTI, despite a significant 33.7% decline in Stelara sales due to biosimilar competition. The MedTech segment also grew by 2.5%, boosted by the recent acquisition of Shockwave Medical and continued strength in Cardiovascular and Vision product lines. The company reported a substantial increase in net earnings to $11.0 billion from $3.3 billion in the prior year's quarter. This significant jump was largely influenced by the reversal of approximately $7.0 billion related to the previously accrued talc reserve, which had a material positive impact on the 'Other (income) expense, net' line item. Excluding this one-time item, operational performance remains solid, demonstrating the company's ongoing ability to drive growth across its diverse portfolio.

Financial Highlights

51 data points

Beta

Revenue

$21.89B

0.7% Gross Margin

Net Income

$11.00B

0.5% Net Margin

EPS (Diluted)

$4.54

Total Assets

$193.67B

Cash & Equivalents

$38.47B

Free Cash Flow

$3.38B

Financial Statements

Beta

Revenue	$21.89B
Cost of Revenue	$7.36B
Gross Profit	$14.54B
SG&A Expenses	$5.11B
Net Income	$11.00B
EPS (Basic)	$4.57
EPS (Diluted)	$4.54
Shares Outstanding (Basic)	2.41B
Shares Outstanding (Diluted)	2.42B

Key Highlights

1Worldwide sales increased by 2.4% to $21.9 billion, driven by a 4.2% operational increase.
2Innovative Medicine segment sales grew 2.3% to $13.9 billion, with Oncology being a key growth driver.
3MedTech segment sales increased 2.5% to $8.0 billion, bolstered by the Shockwave Medical acquisition.
4Net earnings surged to $11.0 billion, significantly impacted by the reversal of a $7.0 billion talc reserve.
5The company completed a significant $9.2 billion issuance of senior unsecured notes to fund the acquisition of Intra-Cellular Therapies, Inc.
6Despite strong overall growth, Stelara sales saw a significant 33.7% decline due to biosimilar competition.
7Earnings per share (EPS) increased significantly to $4.54 (diluted) from $1.34 in the prior year's quarter.

JOHNSON & JOHNSON Quarterly Report for Q1 Ended Mar 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions